ZetaMet™ is a first-of-its kind molecular pathway designed to suspend cancer, inhibit pain, and regenerate bone.
ZetaMet™ is presently in Phase 2a clinical trials for treatment of metastatic breast cancer lesions to bone as part of advanced stage cancer therapy.
ZetaMAST™ is a proprietary hydrogel carrier containing a tailored concentration of our small molecule, designed for a single intra-tumoral injection to treat metastatic lesions in soft tissue organs.
Funding will support the progression of Company’s R&D efforts of additional oncological pipeline assets as well as ancillary osteologic treatments.
SYRACUSE, N.Y., August 11, 2023–(BUSINESS WIRE)–Zetagen Therapeutics, a private, clinical-stage, biopharmaceutical company focused on driving breakthrough innovation in the treatment of metastatic cancers to bone and soft tissue organs as well as osteologic interventions, today announced the close of $9.79 million USD Series B funding round.
“We are pleased to have reached this key milestone in the advancement of Zetagen as a biopharmaceutical company,” said Joe C. Loy, CEO of Zetagen Therapeutics. “We have a robust and diverse pipeline of oncologic treatments in various stages of development and this funding will accelerate each asset, as well as build out the necessary expertise required to bring these important therapies to fruition.”
The Company has been issued two Breakthrough Device Designations from the U.S. Food and Drug Administration (FDA) for ZetaMet™ and ZetaFuse® and issued multiple patents from the U.S. Patent and Trademark Office (USPTO). Zetagen is funded through Series A and B rounds of funding, Phase I and II National Institute of Health (NIH) / National Cancer Institute (NCI) grants and angel investors.